A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
“The only such compound to reach Phase 3 testing was semagacestat, but the trial was terminated after ~12 months of dosing due to adverse events (Doody et al, 2013).”
BackgroundAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Self-citationTargeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., Yang, S. X., & Ivy, S. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.61 · Cited by 1,298
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Sex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
Kametani, F., & Hasegawa, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00025 · Cited by 836
“Notably, the symptoms of AD worsened in a clinical trial of γ-secretase inhibitor (Doody et al., 2013).”
BackgroundThe use of brain organoids to investigate neural development and disease
Di Lullo, E., & Kriegstein, A. R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.107 · Cited by 788
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
“The trial was terminated early on the recommendation of the data and safety monitoring board: cognitive decline worsened with therapy 32,36 , probably due to the deleterious inhibition of other substrates of gamma secretase, resulting, among other adverse effects, in an increased incidence of skin…”
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Self-citationSchneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Mehta, D., Jackson, R., Paul, G., Shi, J., & Sabbagh, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323868 · Cited by 607
“The phase 3 trial was terminated by recommendation of the Data and Safety Monitoring Board [16].”
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Raja, W. K., Mungenast, A. E., Lin, Y.-T., Ko, T., Abdurrob, F., Seo, J., & Tsai, L.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161969 · Cited by 569
The road to restoring neural circuits for the treatment of Alzheimer's disease
Canter, R. G., Penney, J., & Tsai, L.-H. (2016) · Nature · doi:10.1038/nature20412 · Cited by 565
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Penninkilampi, R., Casey, A.-N., Singh, M. F., & Brodaty, H. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180439 · Cited by 520
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
Hwang, T. J., Carpenter, D., Lauffenburger, J. C., Wang, B., Franklin, J. M., & Kesselheim, A. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6008 · Cited by 442
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
“The lack of expected therapeutic effects and – in the case of semagacestat – accelerated cognitive decline compared with the placebo control group were the reasons behind the exclusion of these drugs from clinical trials [1,16,37].”
BackgroundTherapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
“…such as semagacestat and avagacestat were found to cause deterioration of cognitive function and severe adverse effects such as transient bowel obstruction in patients with mild cognitive impairment (MCI) and mild to moderate AD (Coric et al., 2015; Doody et al., 2013; Kumar et al., 2018).”
BackgroundThe contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
Minter, M. R., Taylor, J. M., & Crack, P. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13411 · Cited by 451
Economic burden of Alzheimer disease and managed care considerations
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88482 · Cited by 398
Webster, L., Groskreutz, D., Grinbergs-Saull, A., Howard, R., O’Brien, J. T., Mountain, G., Banerjee, S., Woods, B., Perneczky, R., Lafortune, L., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179521 · Cited by 415
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
“However, the γ-secretase inhibitor semagacestat failed to achieve the primary endpoints in Phase III clinical trials because of worsening symptoms in some patients (NCT00762411, NCT00594568, and NCT01035138) [40].”
BackgroundSosna, J., Philipp, S., Albay, R., Reyes-Ruiz, J. M., Baglietto-Vargas, D., LaFerla, F. M., & Glabe, C. G. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0244-x · Cited by 406
“Semagacestat, an inhibitor of γsecretase which creates the carboxyl terminus of Aβ accelerated the decline in cognitive function in clinical trials [4].”
BackgroundThe amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Sun, L., Zhou, R., Yang, G., & Shi, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618657114 · Cited by 382
Emerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
Self-citationNew Insights Into the Pathogenesis of Alzheimer's Disease
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 344
Alzheimer’s disease, dementia, and stem cell therapy
Duncan, T., & Valenzuela, M. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0567-5 · Cited by 338
“Many pharmacological approaches have attempted to promote amyloid clearance by vaccination [2] and decrease production via secretase inhibition [3].”
γ-Secretase in Alzheimer’s disease
Hur, J.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00754-8 · Cited by 310
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330
Wang, H., Sui, H., Zheng, Y., Jiang, Y., Shi, Y., Liang, J., & Zhao, L. (2019) · Nanoscale · doi:10.1039/c9nr01255a · Cited by 324
The Impact of Systemic Inflammation on Alzheimer’s Disease Pathology
Xie, J., Van Hoecke, L., & Vandenbroucke, R. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.796867 · Cited by 324
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
“Other studies, however, did not find significant differences in levels of Ab1–42 or Ab1–40 compared to a placebo group (Siemers et al. 2006; Galasko et al. 2007; Fleisher et al. 2008; Portelius, Zetterberg, et al. 2012; Doody et al. 2013; Imbimbo et al. 2013; Doody et al. 2015).”
ResultThe Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314
“…rates, including orolabial herpes relapse, and upper respiratory infections, have been reported in clinical trials of ß- or γ-secretase inhibitors [Green et al., 2009; Doody et al., 2013; AlzForum (n.d.-d, h, m)] and the Aßbinding compound ELND005 (Salloway et al., 2011; Alonso et al., 2014).”
BackgroundVassar, R., Kuhn, P., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., & Lichtenthaler, S. F. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12715 · Cited by 311
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Recognition of the amyloid precursor protein by human γ-secretase
Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., & Shi, Y. (2019) · Science · doi:10.1126/science.aaw0930 · Cited by 304
“Unfortunately, perhaps because they also inhibit Notch cleavage (27), g-secretase inhibitors cause severe side effects without any clear clinical benefits to AD patients.”
BackgroundManagement of oxidative stress and other pathologies in Alzheimer’s disease
Simunkova, M., Alwasel, S. H., Alhazza, I. M., Jomova, K., Kollar, V., Rusko, M., & Valko, M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02538-y · Cited by 303
Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303
“Whereas some remain in phase III trials, several have been discontinued because of adverse events (AEs) [16], worsened outcomes [17,18], or lack of benefit [16,19].”
BackgroundSelf-citationLessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Tau-aggregation inhibitor therapy for Alzheimer's disease
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 262
“IDENTITY2) [7]”
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease
Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280
“However, thus far almost all the “promising” drug candidates targeting Aβ associated pathology have been reported failure in clinical trials.(4-6) Therefore, it is time to”
BackgroundSelf-citationKarran, E., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275
“Trials were halted after interim analysis showed increased incidence of skin cancer and worsening of cognition and activities of daily living.(78)”
MethodLessons from a failed γ-secretase Alzheimer trial
De Strooper, B. (2014) · Cell · doi:10.1016/j.cell.2014.10.016 · Cited by 277
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
Espay, A. J., Vizcarra, J. A., Marsili, L., Lang, A. E., Simon, D. K., Merola, A., Josephs, K. A., Fasano, A., Morgante, F., Savica, R., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000006926 · Cited by 274
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
Thawkar, B. S., & Kaur, G. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.11.010 · Cited by 249
Partial volume correction in quantitative amyloid imaging
Su, Y., Blazey, T. M., Snyder, A. Z., Raichle, M. E., Marcus, D. S., Ances, B. M., Bateman, R. J., Cairns, N. J., Aldea, P., Cash, L., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.058 · Cited by 247
“There currently are no proven diseasemodifying treatments (Aisen, 2009; Aisen et al., 2011; Doody et al., 2013; Huang and Mucke, 2012).”
BackgroundAlzheimer’s Amyloid-β is an Antimicrobial Peptide: A Review of the Evidence
Gosztyla, M. L., Brothers, H. M., & Robinson, S. R. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171133 · Cited by 245
Calcium signaling in Alzheimer's disease & therapies
Tong, B. C.-K., Wu, A. J., Li, M., & Cheung, K.-H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.018 · Cited by 231
Structural basis of Notch recognition by human γ-secretase
Yang, G., Zhou, R., Zhou, Q., Guo, X., Yan, C., Ke, M., Lei, J., & Shi, Y. (2019) · Nature · doi:10.1038/s41586-018-0813-8 · Cited by 238
Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
“For example, a phase 3 clinical trial showed that Semagacestat (LY-450139) did not improve cognitive abilities and, in the case of patients receiving a higher dose, caused a worsening of functional capacity, as well as an increased risk of skin cancer and infections [77].”
BackgroundAnalyzing dendritic spine pathology in Alzheimer’s disease: Problems and opportunities
Dorostkar, M. M., Zou, C., Blazquez-Llorca, L., & Herms, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1449-5 · Cited by 235
“Our observation of reducing dendritic spine numbers in vivo following γ-secretase inhibition might offer a potential explanation why Alzheimer’s disease patients treated with a potent γ-secretase inhibitor (semagacestat) showed, among other side effects, a worsening of cognition in the high dose cohort, which caused a…”
BackgroundGaikwad, S., Puangmalai, N., Bittar, A., Montalbano, M., Garcia, S., McAllen, S., Bhatt, N., Sonawane, M., Sengupta, U., & Kayed, R. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109419 · Cited by 234
Goyal, D., Shuaib, S., Mann, S., & Goyal, B. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00116 · Cited by 227
Why do so many clinical trials of therapies for Alzheimer's disease fail?
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228
Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs: A Systematic Review and Meta-analysis
Alves, F., Kalinowski, P., & Ayton, S. (2023) · Neurology · doi:10.1212/wnl.0000000000207156 · Cited by 212
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
Macdonald, R., Barnes, K., Hastings, C., & Mortiboys, H. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170501 · Cited by 217
Drachman, D. A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.11.003 · Cited by 224
“[60] Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al.”
BackgroundThe role of the immune system in Alzheimer disease: Etiology and treatment
Jevtic, S., Sengar, A. S., Salter, M. W., & McLaurin, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.005 · Cited by 215
“For example, a phase 3 trial of semagacestat, a general γ-secretase inhibitor, was halted due to associations with worsening cognitive function and skin cancer development (Doody et al., 2013).”
BackgroundRecent progress of drug nanoformulations targeting to brain
Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.004 · Cited by 213
Lauritzen, I., Pardossi-Piquard, R., Bourgeois, A., Pagnotta, S., Biferi, M.-G., Barkats, M., Lacor, P., Klein, W., Bauer, C., & Checler, F. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1577-6 · Cited by 219
Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0607 · Cited by 218
“In one of these studies evaluating the g-secretase inhibitor LY450139 in patients with Alzheimer disease, NOTCH inhibition was associated with the occurrence of squamous-cell cancers of the skin in elderly patients (15).”
BackgroundMouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
“A lack of success of promising therapeutics for AD [65, 71, 107, 231] has recently been reinforced by the departure of a discouraged Pfizer from the field.”
BackgroundRaskin, J., Cummings, J., Hardy, J., Schuh, K., & Dean, R. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150701103107 · Cited by 188
“These genes account for a small percentage of AD cases and typically occur in patients with the onset of clinical symptoms midlife [19, 20].”
Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S.-Y., Du, M.-Q., & Liu, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1206572 · Cited by 165
“However, in a later Phase III trial (NCT00594568), the trial was terminated because of weight loss in patients treated with semagacestat and significantly higher rates of AEs, such as skin cancer and infection, than in the placebo group (Doody et al., 2013; Henley et al., 2014).”
BackgroundNovel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H.-Y., & Lin, C.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 176
“Semagacestat γ-secretase inhibitor Mild to moderate AD Phase III Lack of efficacy, skin cancer, weight loss, hematologic disorder, infection [28]”
BackgroundStructural basis of γ-secretase inhibition and modulation by small molecule drugs
Yang, G., Zhou, R., Guo, X., Yan, C., Lei, J., & Shi, Y. (2021) · Cell · doi:10.1016/j.cell.2020.11.049 · Cited by 189
Recognition of the Amyloid Precursor Protein by Human gamma-secretase: 6iyc
Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., & Shi, Y. (2020) · Worldwide Protein Data Bank · doi:10.2210/pdb6iyc/pdb · Cited by 185
Notch signaling as a novel regulator of metabolism
Bi, P., & Kuang, S. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.02.006 · Cited by 183
Reactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer’s disease
Price, B. R., Johnson, L. A., & Norris, C. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101335 · Cited by 177
Xu, W., Weissmiller, A. M., White, J. A., Fang, F., Wang, X., Wu, Y., Pearn, M. L., Zhao, X., Sawa, M., Chen, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82409 · Cited by 182
TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance
Xiang, X., Werner, G., Bohrmann, B., Liesz, A., Mazaheri, F., Capell, A., Feederle, R., Knuesel, I., Kleinberger, G., & Haass, C. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606370 · Cited by 183
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.